Advertisement

Oncologists Share New Insights on HER2+ Early-Stage Breast Cancer Management

SPONSORED

In this roundtable discussion, 4 renowned leaders in the breast cancer space share exclusive experiences and information on how they counsel their patients through a breast cancer diagnosis, highlight current guideline recommendations for treating early versus metastatic breast cancer, identify factors that guide their treatment approach, and also weigh the benefits of quicker treatment options versus others that are more time-consuming. Be sure to check out this 4-part series for the most recent updates!


HER2+ Early-Stage Breast Cancer Roundtable: Counseling Patients to Understand Their Diagnosis

This video highlights various strategies our oncologists use to counsel their patients to better understand their breast cancer diagnosis by discussing the associated risk factors, the heterogenous nature of the condition, and the factors that influence appropriate treatment selection.


HER2+ Early-Stage Breast Cancer Roundtable: Standard of Care and Alternative Options for Breast Cancer Management

video 2

This video highlights the current guideline recommendations for treating early breast cancer as well as the current guidelines for metastatic breast cancer. 


HER2+ Early-Stage Breast Cancer Roundtable: Factors Guiding Treatment Before and After Surgery

video 3 speakers

This video highlights both disease- and patient-specific characteristics that may impact treatment options for the management of early breast cancer, including pre-surgery treatment outcomes, adverse events, chemotherapy de-escalation, and more.


 HER2+ Early-Stage Breast Cancer Roundtable: Discussing Treatment Options With Patients

video 4 speakers

This video highlights approaches to discussing various treatment options available for patients with HER2+ early breast cancer, including intravenous vs subcutaneous therapy, patient preferences such as freedom from the burden of a port-a-cath or fear of needles for intravenous therapy, as well as benefits associated with faster treatment options.